User login
Significant race and health care disparities exist among hospitalized psoriasis patients
Significant racial and health care disparities exist among hospitalized psoriasis patients, according to a recent study by Derek Y. Hsu of the Department of Dermatology at Northwestern University, Chicago, and his coauthors.
Researchers looked at a sample representative of 20% of all U.S. hospitalizations from 2002 to 2012, which showed racial and health care disparities for hospitalization of psoriasis cases. Hospitalization was associated with nonwhite race (Asian odds ratio, 2.08; 95% confidence interval, 1.55-2.78; black OR, 1.65; 95% CI, 1.43-1.89; and multiracial/other OR, 1.54; 95% CI, 1.13-2.11) and insurance status (Medicare OR, 1.33; 95% CI, 1.26-1.40; Medicaid OR, 1.32; 95% CI, 1.25-1.40; and uninsured OR, 1.94; 95% CI, 1.64-2.30). Additionally, length of stay was significantly prolonged for psoriasis patients, the investigators found.
“Patients who were admitted for psoriasis were significantly more likely to be Hispanic, Asian, or multiracial/other compared with Caucasians, less likely to be female and more likely to have Medicare, Medicaid, or be uninsured compared with private insurance,” the authors said in the report. “These patients also had higher odds of multiple chronic conditions.”
The results indicate a need for improved access to regular dermatological care for all patients with psoriasis, the authors concluded.
Read the full article in the Journal of the American Academy of Dermatology.
Significant racial and health care disparities exist among hospitalized psoriasis patients, according to a recent study by Derek Y. Hsu of the Department of Dermatology at Northwestern University, Chicago, and his coauthors.
Researchers looked at a sample representative of 20% of all U.S. hospitalizations from 2002 to 2012, which showed racial and health care disparities for hospitalization of psoriasis cases. Hospitalization was associated with nonwhite race (Asian odds ratio, 2.08; 95% confidence interval, 1.55-2.78; black OR, 1.65; 95% CI, 1.43-1.89; and multiracial/other OR, 1.54; 95% CI, 1.13-2.11) and insurance status (Medicare OR, 1.33; 95% CI, 1.26-1.40; Medicaid OR, 1.32; 95% CI, 1.25-1.40; and uninsured OR, 1.94; 95% CI, 1.64-2.30). Additionally, length of stay was significantly prolonged for psoriasis patients, the investigators found.
“Patients who were admitted for psoriasis were significantly more likely to be Hispanic, Asian, or multiracial/other compared with Caucasians, less likely to be female and more likely to have Medicare, Medicaid, or be uninsured compared with private insurance,” the authors said in the report. “These patients also had higher odds of multiple chronic conditions.”
The results indicate a need for improved access to regular dermatological care for all patients with psoriasis, the authors concluded.
Read the full article in the Journal of the American Academy of Dermatology.
Significant racial and health care disparities exist among hospitalized psoriasis patients, according to a recent study by Derek Y. Hsu of the Department of Dermatology at Northwestern University, Chicago, and his coauthors.
Researchers looked at a sample representative of 20% of all U.S. hospitalizations from 2002 to 2012, which showed racial and health care disparities for hospitalization of psoriasis cases. Hospitalization was associated with nonwhite race (Asian odds ratio, 2.08; 95% confidence interval, 1.55-2.78; black OR, 1.65; 95% CI, 1.43-1.89; and multiracial/other OR, 1.54; 95% CI, 1.13-2.11) and insurance status (Medicare OR, 1.33; 95% CI, 1.26-1.40; Medicaid OR, 1.32; 95% CI, 1.25-1.40; and uninsured OR, 1.94; 95% CI, 1.64-2.30). Additionally, length of stay was significantly prolonged for psoriasis patients, the investigators found.
“Patients who were admitted for psoriasis were significantly more likely to be Hispanic, Asian, or multiracial/other compared with Caucasians, less likely to be female and more likely to have Medicare, Medicaid, or be uninsured compared with private insurance,” the authors said in the report. “These patients also had higher odds of multiple chronic conditions.”
The results indicate a need for improved access to regular dermatological care for all patients with psoriasis, the authors concluded.
Read the full article in the Journal of the American Academy of Dermatology.
FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
T-VEC plus ipilimumab safe, effective in advanced melanoma
Talimogene laherparepvec (T-VEC) combined with ipilimumab was more effective in treating advanced melanoma than either treatment alone, report Igor Puzanov, MD, of Vanderbilt University Medical Center in Nashville, Tenn., and coauthors.
In a phase Ib trial of 19 patients with advanced melanoma, the results showed that 50% had positive responses to the combined immunotherapy, and 44% had durable responses lasting 6 months or longer. At 18 months, 50% of patients showed no progression, and overall patient survival was 67%, the authors reported.
The study’s safety analysis showed no new signs of safety concerns, or of any dose-limiting toxicities.
Read the full study in The Journal of Clinical Oncology.
Talimogene laherparepvec (T-VEC) combined with ipilimumab was more effective in treating advanced melanoma than either treatment alone, report Igor Puzanov, MD, of Vanderbilt University Medical Center in Nashville, Tenn., and coauthors.
In a phase Ib trial of 19 patients with advanced melanoma, the results showed that 50% had positive responses to the combined immunotherapy, and 44% had durable responses lasting 6 months or longer. At 18 months, 50% of patients showed no progression, and overall patient survival was 67%, the authors reported.
The study’s safety analysis showed no new signs of safety concerns, or of any dose-limiting toxicities.
Read the full study in The Journal of Clinical Oncology.
Talimogene laherparepvec (T-VEC) combined with ipilimumab was more effective in treating advanced melanoma than either treatment alone, report Igor Puzanov, MD, of Vanderbilt University Medical Center in Nashville, Tenn., and coauthors.
In a phase Ib trial of 19 patients with advanced melanoma, the results showed that 50% had positive responses to the combined immunotherapy, and 44% had durable responses lasting 6 months or longer. At 18 months, 50% of patients showed no progression, and overall patient survival was 67%, the authors reported.
The study’s safety analysis showed no new signs of safety concerns, or of any dose-limiting toxicities.
Read the full study in The Journal of Clinical Oncology.
FROM THE JOURNAL OF CLINICAL ONCOLOGY